NARA Discovery
NARA Subscribed Scholarly Literature Discovery
Boolean search: climate AND coral · microplastic OR nanoplastic · plastic NOT freshwater · "marine heatwave"
Advanced Search
Topic searches article titles and abstracts. Starts a new search; publisher and year refine it.
Searches article titles and abstracts.
Accepts bare DOI, doi: prefix, or a doi.org URL.
Complete publisher name. Publisher imprints are grouped under their main publisher where applicable.
Exact match by full journal title or ISSN.
–
Refine Results Clear Filters
Collection
NARA Subscribed3
Publisher
Springer Nature3
Journal
Journal of Applied Genetics1
Pharmaceutical Research1
The AAPS Journal1
Publication Year
20232
20161
Anna Plotka results 3 · Newest (Page 1/1, per page 25)
Export CSV Export RIS Export current results · up to 5,000 records
Author: Anna Plotka ×Clear All Filters
Search Results
Utilization of Rosuvastatin and Endogenous Biomarkers in Evaluating the Impact of Ritlecitinib on BCRP, OATP1B1, and OAT3 Transporter ActivityNARA Subscribed
Pharmaceutical Research · 2023 · Vol. 40 · Issue 11 · Springer
Yeamin Huh; Anna Plotka; Hua Wei; Julia Kaplan; Nancy Raha; Justin Towner; Vivek S. Purohit; Martin E. Dowty; Robert Wolk; Manoli Vourvahis; Amanda King-Ahmad; Sumathy Mathialagan; Mark A. West; Sarah Lazzaro; Sangwoo Ryu; A. David Rodrigues
Purpose Ritlecitinib, an inhibitor of Janus kinase 3 and tyrosine kinase expressed in hepatocellular carcinoma family kinases, is in development for inflammatory diseases. This study assessed the impact of ritlecitinib on drug transporters using a probe drug and endogenous biomarkers. Methods In vitro transporter-mediated substrate uptake and inhibition by ritlecitinib and its major metabolite were evaluated. Subsequently, a c...
View Details View Full Text
Leveraging Prior Healthy Participant Pharmacokinetic Data to Evaluate the Impact of Renal and Hepatic Impairment on Ritlecitinib PharmacokineticsNARA Subscribed
The AAPS Journal · 2023 · Vol. 25 · Issue 3 · Springer
Vivek Purohit; Yeamin Huh; Jessica Wojciechowski; Anna Plotka; Stephanie Salts; Jeremias Antinew; Angela Dimitrova; Timothy Nicholas
Ritlecitinib is a selective, covalent, irreversible inhibitor of Janus kinase 3 (JAK3) and the tyrosine kinase expressed in hepatocellular carcinoma (TEC) family kinases. Pharmacokinetics and safety of ritlecitinib in participants with hepatic (Study 1) or renal (Study 2) impairment were to be characterized from two phase I studies. Due to a study pause caused by the COVID-19 pandemic, the study 2 healthy participant (HP) coho...
View Details View Full Text
Highly thermostable RadA protein from the archaeon Pyrococcus woesei enhances specificity of simplex and multiplex PCR assaysNARA Subscribed
Journal of Applied Genetics · 2016 · Vol. 57 · Issue 2 · Springer
Aleksandra Stefanska; Lidia Gaffke; Anna-Karina Kaczorowska; Magdalena Plotka; Slawomir Dabrowski; Tadeusz Kaczorowski
View Details View Full Text